Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications
出版年份 2019 全文链接
标题
Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications
作者
关键词
-
出版物
Cancers
Volume 11, Issue 12, Pages 1943
出版商
MDPI AG
发表日期
2019-12-05
DOI
10.3390/cancers11121943
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Interferons α and β in cancer: therapeutic opportunities from new insights
- (2019) Ernest C. Borden NATURE REVIEWS DRUG DISCOVERY
- Radiotherapy in Combination With Cytokine Treatment
- (2019) Ondrej Palata et al. Frontiers in Oncology
- Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab
- (2019) M. Christina Cox et al. CLINICAL CANCER RESEARCH
- Interferon Signaling is Diminished with Age and is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
- (2019) Jaclyn Sceneay et al. Cancer Discovery
- In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
- (2019) Luciano Castiello et al. Frontiers in Immunology
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study
- (2018) Michael B. Atkins et al. CLINICAL CANCER RESEARCH
- The Critical, Clinical Role of Interferon-Beta in Regulating Cancer Stem Cell Properties in Triple-Negative Breast Cancer
- (2018) Mary R. Doherty et al. DNA AND CELL BIOLOGY
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells
- (2018) Luciano Castiello et al. Cancer Immunology Research
- Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells
- (2018) Minmin Liu et al. CANCER RESEARCH
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
- (2018) Diwakar Davar et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review
- (2017) Kun Chen et al. JOURNAL OF AUTOIMMUNITY
- Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a–LCOR axis
- (2017) Toni Celià-Terrassa et al. NATURE CELL BIOLOGY
- DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats
- (2017) David Brocks et al. NATURE GENETICS
- Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
- (2017) Mary R. Doherty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Type I Interferon in Chronic Virus Infection and Cancer
- (2017) Laura M. Snell et al. TRENDS IN IMMUNOLOGY
- Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells
- (2017) Alessandra Fragale et al. Cancer Immunology Research
- A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
- (2017) Anje Cauwels et al. OncoImmunology
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients
- (2016) Caterina Lapenta et al. JOURNAL OF IMMUNOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer
- (2016) Maria Buoncervello et al. Oncotarget
- Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression
- (2016) Yuliya V. Katlinskaya et al. Cell Reports
- DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
- (2015) David Roulois et al. CELL
- Role of type I interferon in inducing a protective immune response: Perspectives for clinical applications
- (2015) Paola Rizza et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Toxicities of Immunotherapy for the Practitioner
- (2015) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma
- (2015) Carmela Rozera et al. Journal of Translational Medicine
- Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
- (2015) Roberto Latagliata et al. LEUKEMIA & LYMPHOMA
- Drug repurposing in oncology—patient and health systems opportunities
- (2015) Francesco Bertolini et al. Nature Reviews Clinical Oncology
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
- (2012) M Talpaz et al. LEUKEMIA
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
- (2012) Bradley N Bidwell et al. NATURE MEDICINE
- IFN- enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing
- (2011) F. Spadaro et al. BLOOD
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells
- (2011) Mercedes B. Fuertes et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12
- (2011) Stefano M. Santini et al. PLoS One
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- Recombinant interferon-α2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial
- (2009) María E. Miquilena-Colina et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now